Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) with a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients with CLI Due to Buerger's Disease (BD)

NCT02501018 is registered in ClinicalTrials.gov with Lisata Therapeutics, Inc. as lead sponsor.

NCT NCT02501018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02501018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) with a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients with CLI Due to Buerger's Disease (BD)
Lead sponsor
Lisata Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2017
Completion date
May 19, 2022
Enrollment
33 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis obliterans, buerger disease, critical limb ischemia, thromboangiitis obliterans